Opendata, web and dolomites

RNAmpMax SIGNED

Maximization of amplification of next-generation RNA replicon vaccines through synergistic molecular and formulation design

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RNAmpMax project word cloud

Explore the words cloud of the RNAmpMax project. It provides you a very rough idea of what is the project "RNAmpMax" about.

demonstration    protein    molecular    clinical    affordable    expression    single    odowska    polymer    mice    supervision    replicons    overcome    primates    co    linear    reflects    karolinska    disparity    initial    dose    pdna    self    nucleus    imperial    maria    mrna    penetration    strand    sk    doses    polyplex    synthetic    modifications    cutting    maximizing    cascade    fellow    prof    oligonucleotides    rna    first    vaccines    trials    possess    paired    curie    limiting    nonhuman    robin    translational    formulation    demonstrated    college    scaled    designed    mirror    adaptions    platform    localization    interferon    have    excellent    dna    plasmid    stevens    formulated    world    amplification    institutet    polymeric    leader    orders    therapeutics    synergistic    london    acid    worldwide    scalability    combination    intend    tested    inhibits    incorporates    inhibit    molly    biomaterials    magnitude    synthesized    nucleic    relationship    efficient    secondment    generation    minimize    as    shattock    messenger    engineer    barrier    edge    restricts   

Project "RNAmpMax" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-02   to  2021-01-01

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 183˙454.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

As a Maria Skłodowska-Curie Fellow, I aim to develop formulated next-generation RNA replicons that are designed to overcome the limiting initial type I interferon response that inhibits amplification and protein expression. RNA replicons are currently a cutting edge nucleic acid platform for delivery of vaccines and therapeutics, as they do not require penetration into the nucleus like plasmid DNA, but possess self-amplification properties that results in more efficient protein expression than messenger RNA. While pDNA and mRNA have have demonstrated excellent results with low doses when tested in mice doses must be scaled up by two orders of magnitude to mirror these effects in nonhuman primates. This disparity reflects a non-linear dose-response relationship, where increased doses are associated with triggering of an interferon cascade which restricts protein expression. Under the supervision of Prof. Robin Shattock, a world leader in translational vaccines and clinical trials at Imperial College London, I aim to overcome this translational barrier for RNA replicons by focusing on maximizing protein expression. I intend to engineer synergistic increases in the amplification of RNA replicons through a combination of molecular modifications designed to minimize interferon response and co-delivery with synthetic single-strand oligonucleotides known to inhibit the interferon pathway. These molecular adaptions will be paired with a novel delivery polymer that directly incorporates oligonucleotides into the RNA polyplex, thus ensuring co-localization: to be synthesized in collaboration with Prof. Molly Stevens, a world leader in polymeric biomaterials, during a secondment at the Karolinska Institutet. This project is the first demonstration of synergistic molecular and formulation design to address the non-linear dose-response relationship, and could impact scalability of RNA vaccines and therapeutics making them more affordable and available in Europe and worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RNAMPMAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RNAMPMAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

MegaBiCycle (2019)

The role of megafauna in biogeochemical cycles and greenhouse gas fluxes: implications for climate and ecosystems throughout history

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More